logo
Plus   Neg
Share
Email

UCB Agrees To Buy Ra Pharma In $2.1 Bln Deal

UCB agreed to acquire Ra Pharmaceuticals Inc. (RARX) for $48 per share in cash, valuing the deal at about $2.1 billion, net of Ra Pharma cash.

The cash consideration represents an about 93% premium to Ra Pharma shareholders based on the 30-day volume weighted average closing stock price of Ra Pharma prior to signing.

The companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions.

It is expected to complete the transaction by the end of the first-quarter of 2020.

UCB said that the acquisition will not impact its 2019 financial guidance. It would be dilutive to UCB's mid-term earnings level.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Uber Technologies Inc. (UBER) said Monday that it laid off about 350 employees across several different teams, as part of its final phase of layoffs of the process it began earlier this year. Porsche unveiled a cheaper version of its Taycan all-electric sports car, Taycan 4S. This is the third version of the sports saloon after Taycan Turbo S and Taycan Turbo launched in September. According to Porsche, Taycan 4S is now the new entry-level model in the Taycan series. The new model is available is two versions based on battery sizes. Howard University and Amazon Studios have jointly launched Howard Entertainment. The program is meant to give African-American students and other marginalized populations such as Latinx and Native American students an opportunity to train and study alongside executives in the entertainment industry. The program will begin in January 2020.
Follow RTT
>